Search Results

Fusion Pharmaceuticals Inc. announced the successful completion of the acquisition of all of the issued and outstanding shares of Fusion by a wholly-owned subsidiary of AstraZeneca AB by way of a statutory plan of arrangement under section 192 of the Canada Business Corporations Act, referred to as the Arrangement.

Fusion Pharmaceuticals Inc. announced that at a special meeting of its shareholders, held virtually earlier today, the Shareholders voted in favour of the resolution to approve the previously announced plan of arrangement with a wholly-owned subsidiary of AstraZeneca under the Canada Business Corporations Act pursuant to which AstraZeneca will acquire all of the issued and outstanding shares of Fusion.

Fusion Pharmaceuticals Inc. reported financial results for the first quarter ended March 31, 2024, and provided an update on clinical and corporate developments.

Fusion Pharmaceuticals Inc. today announced that the Company will participate in two upcoming investor conferences.

SAIL Fusion, a medical device company focused on advancing the surgical treatment of sacroiliac joint dysfunction through solutions built upon proven AO principles, today announced the U.S. commercial launch of its novel BowTie Sacroiliac Fusion System.

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) today announced that it has filed and is in the process of mailing the management information circular and proxy statement (the “Circular”) and related materials for the special meeting (the “Meeting”) of Fusion’s shareholders (the “Shareholders”) to approve the previously announced arrangement with AstraZeneca plc (“AstraZeneca”) under the Canada Business Corporations Act (the “Arrangement”).

Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radioconjugates as precision medicines, announced the Company has entered into a definitive agreement to be acquired by AstraZeneca.

SAIL Fusion, a medical device company focused on advancing the surgical treatment of sacroiliac joint dysfunction through solutions built upon proven AO principles, today announced that it has received FDA clearance for its novel BowTie Sacroiliac Fusion System.

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided an update on clinical and corporate developments.

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) today announced that the first patient has been dosed in the Phase 2 portion of the AlphaBreak trial evaluating FPI-2265 (225Ac-PSMA I&T) in patients with metastatic castration-resistant prostate cancer (mCRPC).